CLOs on the Move

Morphic Therapeutic

www.morphictx.com

 
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn`s disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Joanne Gibbons
 Senior Vice President of Regulatory Affairs Profile
William DeVaul
 General Counsel and Corporate Secretary Profile

Similar Companies

Forticell Bioscience

Forticell Bioscience is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FluidForm Bio

FluidForm Bio™ is creating living human tissue for better treatment of disease. Our patented FRESH™ technology is a revolutionary platform designed to build tissue using cells, proteins, and nothing else. Through partnerships with top life science companies, our technology has been validated to produce the highest quality tissue in a variety of applications.    We deliver human tissue that is indistinguishable from the real thing by integrating breakthrough innovations in 3D printing, computational and synthetic biology, AI, and advanced materials science. Our living tissue will offer therapies to countless patients who deserve better treatment options. 

Sartorius Stedim Biotech

Sartorius Stedim Biotech is a Napa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio-Circle

Bio-Circle is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Arixa Pharmaceuticals

Arixa Pharmaceuticals™ is developing oral antibiotics for resistant Gram-negative infections, an urgent need. Our lead program is an oral prodrug of Avibactam®, a broad spectrum beta-lactamase inhibitor recently approved by FDA. We have addressed and solved the medicinal chemistry issues which complicate the prodrugging of this class of compounds, and expect to receive broad composition of matter patent protection.